Prime time for alpha-synuclein.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

28 citing papers in PubMed.

1. Synaptic Vesicle Disruption in Parkinson's Disease: Dual Roles of α-Synuclein and Emerging Therapeutic Targets.Brain sciences · 2025
   Review
2. Pathogenic mechanism underlying parkinsonism induced by neurotoxicants (MPTP and 6-hydroxydopamine) and α-synuclein: a unifying hypothesis.Journal of molecular cell biology · 2025
   Review
3. Synaptic vesicle-omics in mice captures signatures of aging and synucleinopathy.Nature communications · 2025
   Article
4. Distribution of α-synuclein in normal human jejunum and its relations with the chemosensory and neuroendocrine system.European journal of histochemistry : EJH · 2021
   Article
5. Therapeutic genetic variation revealed in diverse Hsp104 homologs.eLife · 2020
   Article
6. Functional cooperation of α-synuclein and VAMP2 in synaptic vesicle recycling.Proceedings of the National Academy of Sciences of the United States of America · 2019
   Article
7. AAA+ Protein-Based Technologies to Counter Neurodegenerative Disease.Biophysical journal · 2019
   Review
8. Potentiating Hsp104 activity via phosphomimetic mutations in the middle domain.FEMS yeast research · 2018
   Article
9. Cell Biology and Pathophysiology of α-Synuclein.Cold Spring Harbor perspectives in medicine · 2018
   Review
10. Defects in trafficking bridge Parkinson's disease pathology and genetics.Nature · 2016
    Review
11. Glia and alpha-synuclein in neurodegeneration: A complex interaction.Neurobiology of disease · 2016
    Review
12. Models of α-synuclein aggregation in Parkinson's disease.Acta neuropathologica communications · 2014
    Review
13. Towards translational therapies for multiple system atrophy.Progress in neurobiology · 2014
    Review
14. Food anticipatory activity behavior of mice across a wide range of circadian and non-circadian intervals.PloS one · 2012
    Article
15. Dopamine and α-synuclein dysfunction in Smad3 null mice.Molecular neurodegeneration · 2011
    Article
16. α-Synuclein binds the K(ATP) channel at insulin-secretory granules and inhibits insulin secretion.American journal of physiology. Endocrinology and metabolism · 2011
    Article
17. Prion-like disorders: blurring the divide between transmissibility and infectivity.Journal of cell science · 2010
    Article
18. Applying Hsp104 to protein-misfolding disorders.Biochemistry and cell biology = Biochimie et biologie cellulaire · 2010
    Review
19. Lipidomic profiling in mouse brain reveals differences between ages and genders, with smaller changes associated with alpha-synuclein genotype.Journal of neurochemistry · 2009
    Article
20. Common key-signals in learning and neurodegeneration: focus on excito-amino acids, beta-amyloid peptides and alpha-synuclein.Journal of neural transmission (Vienna, Austria : 1996) · 2009
    Article

Corrections and comments

• Comment on
  Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis.2006

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as